Fungarest Crema

Quick links to important sections

Fungarest Crema

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fungarest Crema

Quick Facts

Property Description
Active ingredient Ketoconazole (INN)
Form Topical Cream (Crema)
Pharmacological class Azole Antifungal
Route of administration Cutaneous (Topical)
Origin Synthetic Compound (Imidazole Derivative)

The Identity and Classification of Fungarest Crema

Fungarest Crema is a medicinal product defined by its active chemical substance, Ketoconazole, a synthetic imidazole derivative that is classified as an azole antifungal agent. This pharmacological categorization indicates its primary function is to address conditions caused by pathogenic fungi and yeasts. The active ingredient, a well-characterized compound, has been clinically recognized for its efficacy against a broad spectrum of mycotic organisms. Drugs with Ketoconazole are included in essential medicine lists, underscoring its established therapeutic relevance.

Composition, Form, and General Purpose

The product is formulated as a Topical Cream designed strictly for cutaneous administration, distinguishing it from systemic treatments. As a single-ingredient product, Fungarest Crema is specifically positioned as a localized solution, utilizing a hydrophilic cream base to effectively deliver the Ketoconazole directly to the epidermal surface. This topical formulation ensures high local concentration of the active substance, which functions by inhibiting the synthesis of ergosterol, a critical component of the fungal cell membrane. The overall purpose of this targeted approach is to neutralize the growth and proliferation of susceptible fungal organisms directly where the issue manifests, a fundamental step in resolving the underlying skin condition.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. National Institutes of Health

What side effects are possible with Fungarest Crema?

Possible Side Effects and Safety Information

The safety profile for Fungarest Crema (ketoconazole 2% cream) is primarily related to local reactions at the application site, reflecting the minimal systemic absorption of the active ingredient through the skin.

Common Adverse Reactions

Adverse reactions reported in clinical trials and post-marketing experience are largely local and mild in nature. The most common effects (occurring in 1/100 people) include:

  • Application site itching (pruritus)
  • Application site burning sensation
  • Application site redness (erythema)

Less Common and Serious Reactions

In rare cases, the product has been associated with less common adverse effects, such as contact dermatitis. Allergic-type reactions, including symptoms of hypersensitivity or chemical irritation, are possible, and the product should be discontinued if signs of a sensitivity reaction occur.

Safety Warnings and Contraindications

  • Systemic Safety: Unlike oral formulations of ketoconazole, topical application has not been associated with severe systemic adverse effects, such as liver injury (hepatotoxicity) or adrenal insufficiency, due to negligible systemic absorption.
  • Contraindication: The cream is contraindicated in individuals with a known hypersensitivity or allergy to ketoconazole or any of the excipients in the formulation, such as propylene glycol or sodium sulfite anhydrous.
  • Local Use Only: This product is not for ophthalmic use and must not be applied to the eyes.
  • Specific Populations: Safety and effectiveness have not been definitively established for use in pediatric populations. Use during pregnancy or lactation should be undertaken only after a professional assessment of the potential benefits versus the risks, as it is unknown if sufficient absorption occurs to appear in breast milk.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Ketoconazole Topical Cream distinguishes between localized effects from excessive use and the critical risks associated with accidental ingestion.

Documented Overdose Presentations

Over-application of the cream may result in localized skin reactions at the site of use. Documented manifestations from excessive topical exposure include erythema (redness), oedema (swelling), and a burning sensation. These localized effects are classified as self-limiting and are officially expected to resolve upon discontinuation of the treatment.

Immediate Emergency Actions

The primary serious risk is associated with accidental ingestion of the product. In this event, regulatory guidance mandates immediate contact with a Poison Control Center or emergency room.

Urgent assistance from emergency services must be sought immediately if the victim exhibits severe outcomes following ingestion, such as collapse, a seizure, trouble breathing, or being unable to be awakened.

Official Management Procedures

The required treatment for accidental ingestion consists of supportive and symptomatic measures. A critical procedural contraindication is explicitly documented: to prevent the risk of aspiration, neither emesis (inducing vomiting) nor gastric lavage should be performed.

Therapeutic Uses of Fungarest Crema

The therapeutic utility of Fungarest Crema is commonly used for managing relief for common superficial infections caused by fungi and yeasts, supporting the patient by easing the physical discomfort associated with these conditions. The cream is indicated for several key fungal and yeast conditions.

This topical treatment is applied in clinical settings that involve acute or unstable symptom patterns associated with dermatophytoses (such as Tinea Corporis, Tinea Cruris, and Tinea Pedis), as well as Cutaneous Candidiasis and the management of Pityriasis Versicolor and Seborrheic Dermatitis on the body. It is relevant in contexts marked by increased discomfort and is primarily used to address symptom clusters that may become disruptive.

“This application may assist with managing visible symptoms like flaking and discoloration, while supporting the patient during difficult episodes by easing distress.”

The medication is commonly applied to manage symptoms related to inflammatory or irritative states, such as pruritus (itching) and pronounced erythema (redness). By addressing this irritation, it contributes to easing day-to-day comfort and stability, allowing patients to cope more steadily with temporary functional strain.

Quick Fact: Relief for Key Symptoms
Focuses on easing pruritus (itching) and pronounced erythema (redness) that accompany the infection, contributing to comfort during symptomatic periods.

Regulatory References

  1. U.S. National Library of Medicine's DailyMed overview

Eligibility and Restrictions for Use

The eligibility for using Fungarest Crema (topical ketoconazole 2%) is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional use.

Eligibility Scope

Category Eligibility Rule
Populations for Whom Use is Contraindicated Persons with known hypersensitivity to the active ingredient, ketoconazole, or any excipients in the cream formulation.
Age-Related Eligibility Rules Adults may use the cream. Safety and effectiveness have not been established in children younger than 12 years of age.
Pregnancy and Lactation Eligibility Status Pregnancy: Classified as Category C, meaning the drug should be used only if the potential benefit justifies the potential risk to the fetus. Lactation: Permitted, as systemic absorption is minimal and unlikely to affect the infant.
Condition-Specific Eligibility Rules Caution is advised for patients with sulfite sensitivity because the formulation may contain sodium sulfite anhydrous, which can cause allergic-type reactions or asthmatic episodes.
Eligibility-Related Restrictions The cream is not for ophthalmic use. Use must be discontinued if a reaction suggesting irritation or sensitivity occurs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Fungarest Crema (topical ketoconazole) is determined by its minimal to non-detectable systemic absorption following cutaneous administration. Because the active ingredient is not absorbed into the bloodstream in significant amounts, the systemic drug interactions commonly associated with oral ketoconazole, such as those mediated by CYP3A4 enzyme inhibition, are not observed with the topical cream [NIH].

Pharmacokinetic and Systemic Interaction Profile

Interaction Type Status in Regulatory Documents
Systemic Exposure Not detectable at the 5 ng/mL level in plasma [DailyMed]
Formal Interaction Studies Formal studies have not been performed for the topical formulation [FDA]
Food or Drink Interactions Officially documented as having no known interactions [NHS/GOV.UK]

Although the risk is theoretical for the cream, regulatory documents include caution regarding co-administration with HMG-CoA reductase inhibitors (e.g., simvastatin, lovastatin) that are metabolized by CYP3A4, referencing the known risk associated with systemic ketoconazole [FDA].

Administration Timing Constraint

When co-administered with a mild topical corticosteroid cream, a separation of administration time is advised. Regulatory-aligned guidance suggests applying the two products at separate times of the day to maintain an adequate time gap between applications [NHS/GOV.UK].

Contraindication

Co-administration is formally contraindicated in persons with a known hypersensitivity to the active ingredient, Ketoconazole, or to certain excipients, such as sodium sulfite anhydrous [DailyMed].

Mechanism of Action

Blocking the Fungal Ergosterol Production Pathway

Fungarest Crema's mechanism of action centers on its active ingredient, ketoconazole, which functions as an inhibitor of the fungal enzyme cytochrome P450 14alpha-demethylase (CYP51A1). This enzyme is a vital component of the ergosterol biosynthesis pathway specific to fungi. By binding to and blocking this enzyme, the drug prevents the conversion of lanosterol into ergosterol, the primary sterol required for maintaining the structure and fluidity of the fungal cell membrane.


Disruption of Fungal Cell Membrane Integrity

The resulting depletion of ergosterol and the subsequent accumulation of toxic 14alpha-methylated sterol precursors compromise the functional and structural integrity of the fungal membrane. This molecular cascade leads to increased membrane permeability and leakage of essential intracellular contents. The failure of this critical system impairs the fungus's metabolic and reproductive processes, leading ultimately to the cessation of fungal growth and structural failure of the cell.

Dosage and Administration Information

Fungarest Crema contains the active substance ketoconazole in a topical 2% formulation, which is approved exclusively for cutaneous administration. The administration route is restricted to dermatologic use and is not intended for ophthalmic application. The general principle for use requires applying a sufficient amount of the cream to cover the affected area and the immediate surrounding skin, which is then gently rubbed in.

The official application schedule and required treatment duration are predetermined by the specific condition being managed, reflecting standardized usage protocols.

Official Administration Schedules

Condition Frequency Typical Duration
Tinea Corporis, Tinea Cruris, Cutaneous Candidiasis, Pityriasis Versicolor Once daily 2 weeks
Seborrheic Dermatitis Twice daily 4 weeks
Tinea Pedis (Athlete's Foot) Once daily 6 weeks

The application protocol is structured by key administrative constraints. If no clinical improvement is observed after the specified treatment duration, the diagnosis must be re-evaluated. Furthermore, the safety and effectiveness of this specific topical formulation have not been established for use in pediatric patients. The standardized usage parameters require discontinuation if irritation or sensitivity related to the cream is noted during the course of treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fungarest Crema

Research evidence helps show what has been observed so far about the active ingredient in Fungarest Crema (ketoconazole) and the conditions it was studied for. The findings describe group patterns, not personal outcomes, and are based on clinical trials and scientific reviews conducted and monitored by researchers.

Evidence for Use in Dermatophytoses (Ringworm, Jock Itch, and Athlete’s Foot)

Studies were conducted during periods of increased symptom activity for conditions like Tinea Corporis (ringworm), Tinea Cruris (jock itch), and Tinea Pedis (athlete’s foot). The research base for these infections includes multiple clinical trials, primarily Randomized Controlled Trials (RCTs). These trials used the cream formulation to measure how symptoms evolved in the observed populations, and included trials that used a non-active cream or other established antifungal treatments as comparators.

Researchers monitored outcomes related to physical discomfort and the visible signs of irritation. Specifically, studies explored short-term symptom changes by measuring changes in clinical signs like redness (erythema), scaling, and irritation, alongside assessments of mycological status (the fungal status). Comparative trials explored measured outcomes that showed patterns related to those observed for other topical antifungal treatments. The results apply only to the specific populations studied, which were typically adults and adolescents with uncomplicated, clearly diagnosed infections.

Evidence for Use in Seborrheic Dermatitis

The research for this condition, which is characterized by fluctuating or episodic manifestations, includes several systematic reviews and controlled trials. The primary outcomes related to inflammatory or irritative states, such as the overall disease status and the measured changes in scaling, redness, and patient-reported outcomes describing perceived discomfort (itching). Studies reported that the measured outcomes in the active treatment groups showed patterns related to those observed in the vehicle-controlled groups.

Long-Term Evidence and Follow-up Durability

The existing clinical evidence primarily focuses on the acute treatment phase and the immediate post-treatment period. Follow-up durations were limited in many initial registration trials, meaning the research mainly provides insight into short-term changes. Long-term effects are not fully established for many of the conditions studied. Research is ongoing to better characterize the true extent of long-term stability and relapse rates.

Key Studies & References

  1. Ketoconazole Cream U.S. National Library of Medicine Drug Label Information (DailyMed)
  2. WHO Model List of Essential Medicines – 23rd List (2023)

Frequently Asked Questions (FAQ)

Common questions about Fungarest Crema (FAQ)


Q: How quickly does Fungarest Crema start working for skin issues?

According to official product information, clinical improvement, particularly relief from itching (pruritus), may be seen fairly soon after treatment is begun. The full treatment duration, however, is generally required to be completed as prescribed to properly address the infection.


Q: Are there any common reasons why Fungarest Crema might not work for someone?

Regulatory documents state that if a patient shows no clinical improvement after the specified treatment duration, the diagnosis is generally required to be re-evaluated, according to official guidelines. Additionally, stopping the treatment early may result in the recurrence, or return, of the infection.


Q: What is the risk of the infection coming back after stopping Fungarest Crema?

Official documents state that using the cream for the full prescribed duration is recommended. This is specifically advised to reduce the possibility of the infection returning (known as recurrence).


Q: Can I use Fungarest Crema if I am also using a moisturizer?

When using non-medicated topical products like moisturizers, sunscreen, or cosmetics, some official guidance notes a specific time separation, such as at least 20 minutes, between applications. This is a general guide for using multiple products on the same area.


Q: What is the consistency of Fungarest Crema?

The product is formulated as an antifungal agent in an aqueous cream vehicle. This means the base of the cream is water-based. The formulation is designed to facilitate the delivery of the active ingredient, ketoconazole, to the affected skin area.


Q: What should I do if the cream gets into my eyes?

The cream is strictly not for ophthalmic (eye) use. Regulatory instructions state that if contact occurs, the eyes are generally required to be washed immediately and thoroughly with plenty of water.


Q: Does Fungarest Crema have an expiration date I should look out for?

Yes, like all authorized medicines, Fungarest Crema has an expiration date printed on the packaging. This date is generally required to be checked prior to use.


Q: What is the purpose of the non-active ingredients in Fungarest Crema?

The non-active ingredients, known as excipients, form the base of the cream. Their purpose is to help with stability, texture, and the delivery of the active substance, ketoconazole, into the skin.


Q: Is Fungarest Crema a type of steroid cream?

No, the cream is not a steroid. Its active ingredient, ketoconazole, is officially classified as an azole antifungal agent.


Q: Can Fungarest Crema be used for skin dryness or scaling?

The cream is indicated for specific fungal and yeast infections. While it treats conditions that commonly involve scaling and dryness (such as seborrheic dermatitis), it is not officially intended for general skin dryness or scaling alone.


Q: Can Fungarest Crema be used on the face?

The cream is indicated for conditions like seborrheic dermatitis, which often appear on the face. However, it is strictly for external use, and contact with the eyes, nose, or mouth is required to be avoided.


Q: Can adults over 65 use Fungarest Crema without special concerns?

Official studies have not demonstrated problems specifically limiting the usefulness of topical ketoconazole in the elderly. However, like any medication, some older patients may be more sensitive to the cream's potential side effects.


Q: Is it normal to see some peeling of the skin while using the cream?

Peeling of the treated skin is listed in official documents as a possible side effect. Other local effects include a burning sensation, itching, or redness at the application site.


Q: Is there any evidence linking Fungarest Crema to changes in skin color?

Official documents do not list skin color changes as a direct adverse reaction to the cream itself. However, when treating the condition pityriasis versicolor, the skin's natural color may take several months to fully return to normal after the treatment is completed.


Q: How does Fungarest Crema relate to shampoos with the same active ingredient?

The cream and the shampoo are different dosage forms intended for different primary uses (skin infection vs. scalp seborrheic dermatitis/dandruff) with distinct application instructions. They are not interchangeable.


Q: Are there particular types of clothing that should be avoided while using this cream?

For specific infections like athlete’s foot or jock itch, regulatory guidance often notes avoiding tight-fitting clothing or socks made of synthetic materials (e.g., nylon). The use of clean, cotton items is often recommended in these cases.


Q: Are there any documented cases of resistance developing to the active ingredient?

Based on regulatory information for the cream, the development of microbial resistance to the active ingredient, ketoconazole, has not been reported.


Q: What kind of ingredients are used in the base of the cream (excipients)?

The cream base consists of non-active ingredients which are all listed in the official documents. These include purified water, propylene glycol, cetyl alcohol, stearyl alcohol, polysorbates, and sodium sulfite anhydrous.


Q: Can Fungarest Crema be used by individuals with sensitive skin?

The official instructions advise that if a reaction suggesting irritation or sensitivity occurs, the medication is required to be immediately discontinued.


Q: Is it necessary to wash the skin before each application of Fungarest Crema?

Official patient instructions indicate that the affected area is generally required to be cleaned and thoroughly dried prior to applying the cream.


Q: Does the official product information mention use on nails?

The official indications for the cream include fungal skin infections like tinea pedis (athlete's foot) and tinea cruris (jock itch), but they do not explicitly include onychomycosis (fungal nail infection).


Q: Why is the application area typically limited in size for this kind of medicine?

The treatment area is usually limited to the affected skin and the immediate surrounding area. This is done to keep the medication concentrated locally and to minimize the potential for increased systemic absorption (the amount that gets into the bloodstream).


Q: Can I use Fungarest Crema on an area that is already bandaged or covered?

Official instructions indicate that the treated area is generally not required to be wrapped, covered, or bandaged (occlusive dressing) unless a healthcare professional specifically directs it.


Q: Is the cream described in official documents as suitable for all skin types?

Clinical studies have shown no evidence of contact sensitization or photoallergenic potential in the tested populations. However, the product is contraindicated in persons with a known hypersensitivity to any of its ingredients.

How should Fungarest Crema be stored and disposed of?

Fungarest Crema (Ketoconazole 2% Cream) must be stored and handled according to specific regulatory requirements to ensure product quality and safety.

Mandatory Storage Conditions

The cream is officially required to be stored at 20° to 25°C (68 to 77F), consistent with USP Controlled Room Temperature. The labeling strictly mandates that the product must be protected from freezing and should be stored away from excessive heat. To maintain stability, the tube must be kept tightly closed when not in use.

Child Safety and Disposal

As with all medicines, it is a regulatory requirement that this cream be kept securely out of the sight and reach of children.

For disposal, any unused or expired product must be managed according to local regulations for pharmaceutical waste; it should not be discarded in household trash or poured into a drain unless explicitly authorized by a local authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fungarest Crema found in:

A-Z Index: